Howard B. Moss, M.D.
Name, Degree: Howard B. Moss, M.D.
Role(s) in Task Force and Work Group: DSM-V Taskforce Member, Substance Use Disorder Workgroup
Institutional Affiliation(s): National Institute of Alcohol Abuse and Alcoholism
City, State: Bethesda, MD
Biographical Sketch:
Howard B. Moss, M.D. is the Associate Director for Clinical and Translational Research at National Institute on Alcohol Abuse and Alcoholism in Bethesda, Maryland. He is a board-certified psychiatrist with added qualifications in the subspecialty of Addiction Psychiatry. He has been Professor of Psychiatry at University of Pennsylvania, Temple University, and the University of Pittsburgh. For over 24 years, his research as has focused on the etiology and biopsychosocial liability for substance use disorders and the intergenerational transmission of risk and resilience. This work has employed diverse methodologies that include neurochemistry, psychophysiology, neuroimaging, and molecular and behavioral genetics. Most recently, his research has focused on the diagnostic heterogeneity of alcohol use disorders, including the delineation of subtypes, intermediate phenotypes, endophenotypes, and phenocopies. The goal of these studies is to enhance the efficiency of clinical, genetic and biobehavioral research on alcoholism. The work has also provoked substantial interest in other taxonomic issues in contemporary psychiatry, included the DSM-V.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V: Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
Montgomery County (Maryland) Executive Alcohol and Drug Abuse Advisory Committee |
2007-current |
Committee Member |
The two tables below represent Dr. Moss’s disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Moss has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
None |
|
|
Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
None |
|
|